Corient Private Wealth LP decreased its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 17.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 689,764 shares of the conglomerate's stock after selling 142,161 shares during the quarter. Corient Private Wealth LP owned about 0.10% of Danaher worth $131,388,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC acquired a new stake in Danaher during the fourth quarter valued at $27,000. Clal Insurance Enterprises Holdings Ltd boosted its position in Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate's stock worth $29,000 after purchasing an additional 53 shares in the last quarter. JPL Wealth Management LLC acquired a new stake in Danaher in the third quarter valued at approximately $25,000. N.E.W. Advisory Services LLC purchased a new stake in shares of Danaher in the second quarter valued at approximately $25,000. Finally, Main Street Group LTD acquired a new position in shares of Danaher during the 1st quarter worth approximately $25,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on DHR. Weiss Ratings raised Danaher from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, July 15th. Wolfe Research downgraded Danaher from an "outperform" rating to a "peer perform" rating in a research report on Monday, June 1st. HSBC reduced their price target on Danaher from $270.00 to $230.00 and set a "buy" rating on the stock in a report on Wednesday, June 3rd. Royal Bank Of Canada increased their price target on shares of Danaher from $200.00 to $215.00 and gave the company an "outperform" rating in a research note on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and issued a $240.00 target price on shares of Danaher in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $228.91.
View Our Latest Report on Danaher
Danaher Price Performance
Shares of DHR opened at $200.30 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The stock has a market cap of $140.81 billion, a PE ratio of 35.58, a price-to-earnings-growth ratio of 2.50 and a beta of 0.78. The firm has a fifty day moving average price of $202.65 and a 200 day moving average price of $192.08.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the previous year, the business posted $0.77 earnings per share. Danaher's quarterly revenue was up 5.5% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Corporation will post 8.53 EPS for the current year.
Danaher Profile
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.
The company's portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
